Webinar: Hereditary Cancer Risk Assessment – Benefit vs. Cost within the Scope of Practicing Precision Medicine

Hereditary Cancer Webinar
Hereditary Cancer Webinar

Date: Thursday, September 19, 2019

Time: 8:00 am Pacific Daylight Time / 11:00 am Eastern Daylight Time (GMT-4:00)

Location: Online

Cancer research has led to the identification of inherited gene variants that increase the risk of developing certain kinds of cancer during one’s lifetime. In this webinar, Dr. Lina Abi Mosleh from Ayass Bioscience will introduce the Ayass Hereditary Cancer Risk Assessment Test which uses a targeted and cost-effective approach to detect over 250 variants associated with leukemia, ovarian, breast, prostate, pancreatic, lung and skin cancers.

Learning Objectives:

  • Importance of genetic inherited cancer risk testing
  • How cancer risk testing can be achieved using a rapid, cost-effective workflow
  • Trade-offs between broad-based sequencing vs targeted approaches

Register Here

Presented by:

Lina Abi Mosleh, Ph.D

Lina Abi Mosleh, Ph.D
Vice President & Principal Scientist, Ayass BioScience LLC

Lina is the Vice President and Principal Scientist at Ayass Bioscience, LLC with the responsibility to oversee, manage, and lead daily operations in both the clinical and research laboratories. Prior to joining Ayass Bioscience, her career was focused on basic science research in academic institutions where she served as a faculty member. The opportunity presented at Ayass Bioscience allowed her to utilize her skills and dive into the world of translational research by bridging science to patient care. She is involved in the design, development, and validation of high complexity molecular testing from next generation sequencing to array-based genotyping assays. She is also part of a research team that develops aptamers for diagnostic and therapeutic applications, utilizes nanotechnology for diagnostics applications, and identifies and clinically validates new biomarkers for autoimmune disease. One of the company’s most recent projects involved the development of a Thrombosis Risk Assessment Tool called “MoNet”. MoNet is an advanced biological tool that uses CAI (Cognitive Artificial Intelligence) to collect and analyze data from hundreds of molecular tests conducted on thousands of patients at Ayass Bioscience to identify clinical associations between biomarkers and generate a prediction score for an individual’s risk of thrombosis. Lina earned her Bachelor’s and Master’s in Cell Biology at the American University of Beirut in Lebanon. Upon moving to the U.S., Lina received her Ph.D. in Molecular Genetics and Biochemistry at the University of Texas Southwestern Medical Center at Dallas in the laboratory of Nobel laureates Drs. Michael S. Brown and Joseph L Goldstein.